insulin and semaglutide for Prediabetes: A Guide to Preventing Type 2 Diabetes Semaglutide for Weight Loss FAQ's

Patients with genetic markers suggesting slower tolerance may benefit from extended time at lower doses, while those with genetic patterns indicating strong receptor sensitivity might reach their optimal dose more quickly

Triple Agonist Treatment Due to the success of both DualAG approaches and the generally high sequence homology between GLP-1, GIP, and glucagon, the next step in novel pharmaceutical development was the design of chimeric GLP-1R/GIPR/GcgR unimolecular triple-agonists followed by the development of another triple agonist, a GLP-1/glucagon/Y2 receptor triple agonist [85]

There are now even more options available for patients who may be candidates for GLP-1 therapy

No en todos los casos

Some may experience persistent mild appetite suppression or digestive changes, but severe side effects that develop months into treatment are uncommon and warrant medical evaluation